Replies to post #654467 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Maverick0408,

That set aside funding is a good thing as it does provide a fall back. Like I said though, NICE now has the ability to bring their decision up to coincide or nearly coincide with approval decisions. This is a more recent development. Manufacturing is the key to getting personalized treatments to the masses and like I said, I think NICE is offering an early reimbursement decision if Edens is in play so strategic decision making I believe is in play. Best wishes.

[manibiotech]

Yep
Like they are 1000% sure of no deficiencies will be found , so why hurry for submission , let’s wait for reimbursement approvals and wait on submission
Makes perfect sense

[biosectinvestor]

That pot of money that you referred to comes after approval but during the gap period when NICE has not yet acted, though with the new accelerated program in the U.K., NICE can act more concurrently with MHRA, so that period is expected to be much shorter going forward for drugs like DCVax-L.